Evidence map›Paper›PMID 27931238›Full record

ArticleJournal of experimental & clinical cancer research : CR2016

Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase.

Franco Di Filippo, Simona Di Filippo, Anna Maria Ferrari, Raffaele Antonetti, Alessandro Battaglia, Francesca Becherini, Laia Bernet, Renzo Boldorini, Catherine Bouteille, Simonetta Buglioni and 30 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

40 authors at 20 institutions in 4 countries.

Franco Di FilippoRegina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. franco.difilippo@ifo.gov.it.
Simona Di FilippoOspedale di Latina, Latina, Italy.
Anna Maria FerrariSan Camillo, Milan, Italy.
Raffaele AntonettiAz. Ospedaliera Universitaria Foggia, Foggia, Italy.
Alessandro BattagliaASL, Prato, Italy.
Francesca BecheriniULSS 7 Pieve di Soligo, Pieve di Soligo, Italy.
Laia BernetHospital Lluís Alcanyís, Xàtiva, Spain.
Renzo BoldoriniUniversità of Piemonte, Vercelli, Italy.
Catherine BouteilleHôpitaux de Lyon, Lyon, France.
Simonetta BuglioniRegina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
Paolo BurelliULSS 7 Pieve di Soligo, Pieve di Soligo, Italy.
Rafael CanoHospital Universitario de La Ribera, Alzira, Spain.
Vincenzo CanzonieriCentro Regionale Oncologico, Bari, Italy.
Pierluigi Chiodera, San Donato, Italy.
Alfredo CirilliPoliclinico of Bari, Bari, Italy.
Luigi CoppolaSan Filippo Neri, Florence, Italy.
Stefano DragoSan Filippo Neri, Florence, Italy.
Luca Di TommasoHumanitas Rozzano, Rozzano, Italy.
Privato FenaroliASST Papa Giovanni XXIII, Bergamo, Italy.
Roberto FranchiniAzienda Ospedaliera "Maggiore della Carità" di Novara, Novara, Italy.
Andrea GianattiASST Papa Giovanni XXIII, Bergamo, Italy.
Diana GiannarelliRegina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
Carmela GiardinaUniversity of Bari, Bari, Italy.
Florence GodeyEugene Marquis Cancer Center, Rennes, France.
Massimo M GrassiHumanitas Gavazzeni, Bergamo, Italy.
Giuseppe B GrassiSan Filippo Neri, Florence, Italy.
Siobhan LawsHampshire Hospitals NHS Foundation Trust, England, UK.
Samuele MassarutCentro Regionale Oncologico, Bari, Italy.
Giuseppe NaccaratoUniversity of Pisa, Pisa, Italy.
Maria Iole NatalicchioAzienda Ospedaliero-Universitaria OO.RR. Foggia, Foggia, Italy.
Sergio OreficeUniversity of L'Aquila, L'Aquila, Italy.
Fabrizio PalmieriI.R.C.C.S. L. Spallanzani, Rome, Italy.
Tiziana PerinCentro Regionale Oncologico, Bari, Italy.
Manuela RoncellaAzienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Massimo G RoncalliHumanitas, Pisa, Italy.
Antonio RulliUniversity of Perugia, Perugia, Italy.
Angelo SidoniUniversity of Perugia, Perugia, Italy.
Corrado TinterriHumanitas, Pisa, Italy.
Maria C TrugliaUSL, Prato, Italy.
Isabella SperdutiRegina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
Ospedale San Filippo Neri · ITHumanitas University · ITOspedale Papa Giovanni XXIII · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Perugia · ITAzienda Ospedaliera Universitaria Pisana · ITAzienda Universitaria Ospedaliera Consorziale - Policlinico Bari · ITCentre Eugène Marquis · FRFondazione Humanitas per la Ricerca · ITHampshire Hospitals NHS Foundation Trust · GBHospital de La Ribera · ESHospital Lluis Alcanyis · ESHospital of Prato · ITHumanitas Gavazzeni · ITI.R.C.C.S. Oasi Maria SS · ITIRCCS San Camillo Hospital · ITOspedali Riuniti di Foggia · ITUniversity of Bari Aldo Moro · ITUniversity of L'Aquila · ITUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor-positive sentinel lymph node (SLN) biopsy results in a risk of non sentinel node metastases in micro- and macro-metastases ranging from 20 to 50%, respectively. Therefore, most patients underwent unnecessary axillary lymph node dissections. We have previously developed a mathematical model for predicting patient-specific risk of non sentinel node (NSN) metastases based on 2460 patients. The study reports the results of the validation phase where a total of 1945 patients were enrolled, aimed at identifying a tool that gives the possibility to the surgeon to choose intraoperatively whether to perform or not axillary lymph node dissection (ALND).

methodsThe following parameters were recorded: Clinical: hospital, age, medical record number; Bio pathological: Tumor (T) size stratified in quartiles, grading (G), histologic type, lymphatic/vascular invasion (LVI), ER-PR status, Ki 67, molecular classification (Luminal A, Luminal B, HER-2 Like, Triple negative); Sentinel and non-sentinel node related: Number of NSNs removed, number of positive NSNs, cytokeratin 19 (CK19) mRNA copy number of positive sentinel nodes stratified in quartiles. A total of 1945 patients were included in the database. All patient data were provided by the authors of this paper.

resultsThe discrimination of the model quantified with the area under the receiver operating characteristics (ROC) curve (AUC), was 0.65 and 0.71 in the validation and retrospective phase, respectively. The calibration determines the distance between predicted outcome and actual outcome. The mean difference between predicted/observed was 2.3 and 6.3% in the retrospective and in the validation phase, respectively. The two values are quite similar and as a result we can conclude that the nomogram effectiveness was validated. Moreover, the ROC curve identified in the risk category of 31% of positive NSNs, the best compromise between false negative and positive rates i.e. when ALND is unnecessary (<31%) or recommended (>31%).

conclusionsThe results of the study confirm that OSNA nomogram may help surgeons make an intraoperative decision on whether to perform ALND or not in case of positive sentinel nodes, and the patient to accept this decision based on a reliable estimation on the true percentage of NSN involvement. The use of this nomogram achieves two main gools: 1) the choice of the right treatment during the operation, 2) to avoid for the patient a second surgery procedure.

Indexed as

NomogramsBreast NeoplasmsFemaleGene DosageHumansIntraoperative PeriodKeratin-19Lymphatic MetastasisLymph Node ExcisionModels, TheoreticalNeoplasm GradingNeoplasm MicrometastasisNucleic Acid Amplification TechniquesRetrospective StudiesROC CurveKeratin-19CK19 mRNA number copiesNomogramNon Sentinel Node statusOSNA method

Identifiers

PMID27931238
PMCPMC5146809
OpenAlexW2560664318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.